Eli Lilly, one of the world's largest pharmaceutical companies, has made a significant acquisition by purchasing Atai Beckley for $2.8 billion. This move comes as part of Eli Lilly’s strategy to explore new treatments for depression, particularly focusing on a DMT-like nasal spray that is expected to enter Phase 3 clinical trials in 2029.
The deal represents a strategic investment into the field of psychedelic therapies, which have shown promise in treating various mental health conditions. Atai Beckley has been working on developing a novel treatment for depression using DMT (Dimethyltryptamine), a psychoactive compound found naturally in plants like San Pedro cactus and Ayahuasca.
This acquisition follows J&J's success with SPRAVATO, which generated $468 million in Q1 of 2026. The pharmaceutical industry has been increasingly interested in exploring the potential of psychedelic compounds for treating depression, a condition that affects millions worldwide but often remains resistant to conventional treatments.
[1] provides detailed insights into Eli Lilly's acquisition strategy and its focus on developing new therapies, while [2] highlights J&J’s success with SPRAVATO. Both sources emphasize the growing interest in psychedelic research within the pharmaceutical sector.